BioVie (BIVI) to Release Quarterly Earnings on Wednesday

BioVie (NASDAQ:BIVIGet Free Report) will release its earnings data on Wednesday, February 7th.

BioVie (NASDAQ:BIVIGet Free Report) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.29) EPS for the quarter. On average, analysts expect BioVie to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioVie Trading Down 3.7 %

BIVI stock opened at $1.03 on Tuesday. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 0.39. BioVie has a 12 month low of $0.89 and a 12 month high of $11.39. The firm has a 50-day moving average of $1.40 and a two-hundred day moving average of $2.90.

Institutional Trading of BioVie

Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Group AG boosted its position in shares of BioVie by 284.2% during the 4th quarter. UBS Group AG now owns 3,565 shares of the company’s stock worth $28,000 after purchasing an additional 2,637 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of BioVie by 2,706.5% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,294 shares of the company’s stock worth $35,000 after purchasing an additional 4,141 shares during the period. AQR Capital Management LLC purchased a new position in shares of BioVie during the 3rd quarter worth approximately $50,000. Charles Schwab Investment Management Inc. purchased a new position in shares of BioVie during the 2nd quarter worth approximately $50,000. Finally, Wells Fargo & Company MN boosted its position in shares of BioVie by 162.3% during the 4th quarter. Wells Fargo & Company MN now owns 7,044 shares of the company’s stock worth $55,000 after purchasing an additional 4,359 shares during the period. Institutional investors and hedge funds own 5.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BIVI shares. Oppenheimer cut their price objective on shares of BioVie from $12.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, November 30th. Cantor Fitzgerald downgraded shares of BioVie from an “overweight” rating to a “neutral” rating in a report on Thursday, November 30th.

Read Our Latest Research Report on BIVI

About BioVie

(Get Free Report)

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.

Read More

Earnings History for BioVie (NASDAQ:BIVI)

Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.